Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 3,345 shares of Lexeo Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $4.95, for a total value of $16,557.75. Following the transaction, the chief executive officer owned 374,472 shares in the company, valued at approximately $1,853,636.40. This represents a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Wednesday, July 1st, Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $4.48, for a total value of $116,242.56.

Lexeo Therapeutics Trading Up 8.9%

Shares of NASDAQ LXEO traded up $0.44 during mid-day trading on Wednesday, reaching $5.37. 941,872 shares of the company’s stock were exchanged, compared to its average volume of 952,662. The firm has a market capitalization of $440.61 million, a price-to-earnings ratio of -4.67 and a beta of 1.46. The business has a fifty day simple moving average of $4.70 and a 200 day simple moving average of $5.56. Lexeo Therapeutics, Inc. has a twelve month low of $3.99 and a twelve month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.01). Equities research analysts predict that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LXEO. BlackRock Inc. bought a new stake in Lexeo Therapeutics during the 2nd quarter worth about $26,717,000. RA Capital Management L.P. bought a new position in shares of Lexeo Therapeutics in the 4th quarter valued at about $49,650,000. Paradigm Biocapital Advisors LP bought a new position in shares of Lexeo Therapeutics in the 4th quarter valued at about $47,299,000. Balyasny Asset Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the second quarter valued at about $16,117,000. Finally, Jupiter Topco LLC bought a new stake in Lexeo Therapeutics during the second quarter worth about $18,409,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LXEO. Wall Street Zen lowered shares of Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday. Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. cut their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Lexeo Therapeutics has a consensus rating of “Buy” and an average price target of $18.75.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.